R01 CA116021/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Save citations to file

Email citations

Subject: R01 CA116021/CA/NCI NIH HHS/United States[Grants - PubMed

To:

From:

Selection:

Format:

MeSH and other data

Add to Collections

Add to My Bibliography

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Results by year

Year	Number of Results
2000	1
2001	1
2004	2
2005	1
2006	3
2007	5
2008	2
2009	5
2010	5
2011	3
2012	5
2013	3
2014	3
2015	6
2016	8
2017	3
2018	1
2019	2
2020	7
2021	7
2022	4
2023	4
2024	2

71 results

Page of 8

Results by year

Page 1

Harnessing the potential of CD40 agonism in cancer therapy.

Zhou Y, Richmond A, Yan C. Zhou Y, et al. Cytokine Growth Factor Rev. 2024 Feb;75:40-56. doi: 10.1016/j.cytogfr.2023.11.002. Epub 2023 Dec 4. Cytokine Growth Factor Rev. 2024. PMID: 38102001 Free article. Review.

CXCR2 chemokine receptor - a master regulator in cancer and physiology.

Lazennec G, Rajarathnam K, Richmond A. Lazennec G, et al. Trends Mol Med. 2024 Jan;30(1):37-55. doi: 10.1016/j.molmed.2023.09.003. Epub 2023 Oct 21. Trends Mol Med. 2024. PMID: 37872025 Review.

CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth.

Yang J, Bergdorf K, Yan C, Luo W, Chen SC, Ayers GD, Liu Q, Liu X, Boothby M, Weiss VL, Groves SM, Oleskie AN, Zhang X, Maeda DY, Zebala JA, Quaranta V, Richmond A. Yang J, et al. Mol Cancer. 2023 Jun 3;22(1):92. doi: 10.1186/s12943-023-01789-9. Mol Cancer. 2023. PMID: 37270599 Free PMC article.

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.

Kumar A, Ramani V, Bharti V, de Lima Bellan D, Saleh N, Uzhachenko R, Shen C, Arteaga C, Richmond A, Reddy SM, Vilgelm A. Kumar A, et al. J Immunother Cancer. 2023 May;11(5):e006019. doi: 10.1136/jitc-2022-006019. J Immunother Cancer. 2023. PMID: 37230537 Free PMC article.

BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.

Bharti V, Watkins R, Kumar A, Shattuck-Brandt RL, Mossing A, Mittra A, Shen C, Tsung A, Davies AE, Hanel W, Reneau JC, Chung C, Sizemore GM, Richmond A, Weiss VL, Vilgelm AE. Bharti V, et al. Cell Rep. 2022 Dec 20;41(12):111826. doi: 10.1016/j.celrep.2022.111826. Cell Rep. 2022. PMID: 36543138 Free PMC article.

BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.

Maurer LM, Daley JD, Mukherjee E, Venier RE, Julian CM, Bailey NG, Jacobs MF, Kumar-Sinha C, Raphael H, Periyapatna N, Weiss K, Janeway KA, Mody R, Lucas PC, McAllister-Lucas LM, Bailey KM. Maurer LM, et al. Cancer Res Commun. 2022 Apr;2(4):220-232. doi: 10.1158/2767-9764.crc-21-0047. Epub 2022 Apr 20. Cancer Res Commun. 2022. PMID: 36187937 Free PMC article.

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer.

Zhang Z, Richmond A, Yan C. Zhang Z, et al. Int J Mol Sci. 2022 Jul 1;23(13):7353. doi: 10.3390/ijms23137353. Int J Mol Sci. 2022. PMID: 35806358 Free PMC article. Review.

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients.

Yan C, Chen SC, Ayers GD, Nebhan CA, Roland JT, Weiss VL, Johnson DB, Richmond A. Yan C, et al. NPJ Precis Oncol. 2022 Jan 20;6(1):6. doi: 10.1038/s41698-021-00249-1. NPJ Precis Oncol. 2022. PMID: 35058553 Free PMC article.

Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy.

Bullock K, Richmond A. Bullock K, et al. Cancers (Basel). 2021 Dec 15;13(24):6293. doi: 10.3390/cancers13246293. Cancers (Basel). 2021. PMID: 34944914 Free PMC article. Review.

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.

Yan C, Richmond A. Yan C, et al. Mol Cancer. 2021 Nov 10;20(1):146. doi: 10.1186/s12943-021-01442-3. Mol Cancer. 2021. PMID: 34758832 Free PMC article. Review.

71 results

Page of 8

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year